India, May 8 -- Viatris Inc. (VTRS), a healthcare company, Thursday said its two Phase 3 studies evaluating MR-107A-02 for the treatment of acute pain met their primary goals.
The studies were conducted in patients- one following herniorrhaphy surgery and the second following bunionectomy surgery. An opioid comparator arm was also included to confirm the sensitivity of the pain model.
Post-operative herniorrhaphy and bunionectomy patients aged 18 years or older who experienced moderate-to-severe pain following surgery were randomized to receive either MR-107A-02, tramadol, an opioid pain medication, or placebo. In both the pain models, MR-107A-02 showed statistically significant and clinically meaningful improvement in pain compared to pl...